CEPI and Dakar Pasteur Institute Partner to Increase Vaccine Access in Africa

CEPI and Pasteur Institute in Dakar Advance Equitable Access to Vaccines in Africa

Today, January 19th, 2023, CEPI and the Pasteur Institute in Dakar announced their collaboration to advance equitable access to vaccines in Africa. CEPI will invest up to 50 million dollars over the next 10 years “in order to combat the type of inequality that characterized the response to COVID-19.”

The agreement will also help Africa reach the African Union’s goal of increasing the share of African manufactured vaccines to 60% by 2040. The Pasteur Institute in Dakar is set to receive a grant of up to 15 million over three years as part of the partnership, with the potential to expand the scope and funding to a total of 50 million.

CEPI’s Executive Director, Richard Hatchett puts emphasis on the fact that “historically, a handful of countries and regions have dominated access to the global supply of vaccines. This has to change if we want the world to have the opportunity to respond quickly and equitably to future outbreaks and pandemics.”

The Director General of the Pasteur Institute in Dakar, Amadou Alpha Sall, says that this initiative “will ensure that regional outbreaks are not neglected by deploying the most advanced technology for the greatest needs.”

The collaboration received financing from the European Union, the European Investment Bank, the French Development Agency, the Islamic Development Bank and the German Government, among others.

Despite the partnership’s optimistic outlook, a study conducted in October of 2022, revealed that 295.8 million infections and 1.3 million deaths globally could have been avoided, if the COVID-19 vaccines had been distributed equitably.

CEPI is a public-private coalition and the Pasteur Institute in Dakar is a Senegalese private foundation, with the mission of promoting public health in Africa since its founding in 1896. The Institute plans to manufacture 300 million doses of vaccine for COVID-19 and other diseases come 2023 in a plant built with support from the European Investment Bank.

Your email address will not be published. Required fields are marked *